Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: Ragul Gowthaman Clear advanced filters

  • Structural immunology is critical in understanding the interplay between the immune response and the infective agent but such studies in T cells and SARS-CoV-2 lag behind those of antibodies and B-cell receptors. Here the authors assess recognition of SARS-CoV-2 spike epitopes and their natural variants by public and private T cell receptors.

    • Daichao Wu
    • Alexander Kolesnikov
    • Roy A. Mariuzza
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-14

  • Developing broadly applicable neoantigen-directed adoptive cell therapies (ACTs) is challenging because each cancer patient has an unique neoantigen repertoire. Here, the authors present the crystal structures of tumor-specific T cell receptors (TCRs) that recognize a shared neoepitope arising from the R175H driver mutation in the p53 oncogene (p53R175H) alone and bound to p53R175H–HLA-A2, which are of interest for the structure-guided design of TCRs to improve T cell potency for ACT.

    • Daichao Wu
    • D. Travis Gallagher
    • Roy A. Mariuzza
    ResearchOpen Access
    Nature Communications
    Volume: 11, P: 1-12

  • Cutaneous gamma-delta T cell lymphomas are rare but aggressive cancers. Here, by DNA, RNA and T cell receptor sequencing, the authors elucidate the molecular ontogeny by revising the cell of origin and identifying potentially targetable mutations.

    • Jay Daniels
    • Peter G. Doukas
    • Jaehyuk Choi
    ResearchOpen Access
    Nature Communications
    Volume: 11, P: 1-14

  • Wu et al. identify an inhibitor to the RNA-binding protein HuR, KH-3, that disrupts the interaction between HuR and target RNAs and inhibits human cancer growth and metastasis in mouse xenograft assays. This study suggests the therapeutic potential of targeting HuR in breast cancer with HuR overexpression.

    • Xiaoqing Wu
    • Gulhumay Gardashova
    • Liang Xu
    ResearchOpen Access
    Communications Biology
    Volume: 3, P: 1-16